Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by diarrhea, abdominal pain, and weight loss. The primary goal of CD treatment is to induce and…
Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. Characterized by the thickening and stiffening of tissues in the lungs, it…
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. SLE symptoms range from general malaise to serious CNS and renal manifestations…
Non-TNF biologics (e.g., IL-17 inhibitors) are gaining momentum in China in the treatment of psoriasis, particularly moderate to severe disease. We expect that the growing psoriasis armamentarium…
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder associated with progressive inflammation and/or fibrosis of the lung tissue. The leading cause of the disorder is unknown. IPF…
TNF-alpha inhibitors (Johnson & Johnson Innovative Medicine’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s Entyvio), and an IL-12/23 inhibitor (Johnson & Johnson Innovative Medicine’s…
Obesity is recognized as a chronic disease and public health concern globally. The primary goals of obesity treatment are to improve patients’ health outcomes and quality of life. Physicians…
Type 2 diabetes (T2D) remains one of the biggest public health concerns in China, where the disease’s prevalence is globally the highest. Biguanides and alpha-glucosidase inhibitors continue to…
Although multiple guidelines recommend treating post-traumatic stress disorder (PTSD) with psychotherapy first, such an approach does not suffice for many patients, necessitating the use of…
Postherpetic neuralgia (PHN) is characterized by itching, numbness, and burning, as well as stabbing, shooting, or shock-like pain. PHN is managed with multiple established, generic antiepileptic…
Ten new brands entered the Parkinson’s disease (PD) market over the last decade (e.g., Acorda’s Inbrija, Sunovion’s Kynmobi, Neurocrine’s Ongentys), and additional new options are advancing…
A wide array of drugs are available to treat osteoporosis. These drugs are generally effective in reducing patients’ risk of fracture and are well tolerated. Oral bisphosphonates, especially…
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 703 currently available and novel biosimilar products, detailing…
In 2022, sales of erythropoiesis-stimulating agent (ESA) brands and biosimilars at the ex-manufacturer price level totaled more than $3.6 billion in the major pharmaceutical markets under study (…
TNF-alpha inhibitors (e.g., Remicade, Humira) are the mainstay of biological treatment for moderate to severe Crohn’s disease (CD), while non-TNF biologics (i.e., Takeda’s Entyvio, a CAM…